Generic Name and Formulations:
Granisetron 3.1mg/24hrs; transdermal delivery system (patch).
Kyowa Kirin, Inc.
Indications for SANCUSO:
Prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.
≥18yrs: apply one patch to clean, dry, intact healthy skin on upper outer arm 24 to 48 hours before chemotherapy; remove at least 24 hours after chemotherapy is completed. May wear patch for up to 7 days. Do not cut patch.
<18yrs: not recommended.
May mask progressive ilieus and/or gastric distention. Avoid direct sun or UV light (cover patch with clothing during use and for 10 days after removing patch). Avoid exposure to external heat sources (eg, heating pads). Pregnancy (Cat.B). Nursing mothers.
5-HT3 receptor antagonist.
Do not take with other granisetron products. Serotonin syndrome possible esp. with concomitant serotonergic drugs.
Constipation; local irritation (remove patch if severe or if generalized skin reaction occurs), headache; serotonin syndrome (discontinue if occurs).
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Oxidized Low-Density Lipoprotein May Predict Risk for Recurrent Stroke
- Inappropriate Prescribing Protocols in Parkinson Disease
- Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis
- Review of Factors Impacting Sport-Related Concussion Headaches
- Congress Passes Bill to Fight Opioid Crisis